InVivoSIM anti-human EGFR (Panitumumab Biosimilar)

About InVivoSIM anti-human EGFR (Panitumumab Biosimilar)

This biosimilar antibody uses the same variable regions as the therapeutic antibody Panitumumab, making it ideal for research use. Panitumumab is a fully humanized IgG2κ monoclonal antibody that reacts with epidermal growth factor receptor (EGFR), a member of the HER tyrosine kinase growth factor receptor family. EGFR binds to EGF family ligands, which sets off a number of signaling pathways that turn extracellular cues into the right responses from cells. EGFR binding with its known ligands including EGF, TGF, AREG, EPGN, BTC, epiregulin (EREG), and heparin-binding EGF triggers receptor homo- and/or heterodimerization, autophosphorylation, and recruitment of adapter proteins like GRB2, thereby activating complex downstream signaling pathways including RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCγ-PKC, STAT modules, and NF-κB. EGFR directly phosphorylates RGS16 for coupling the EGFR signaling to GPCR signaling and also phosphorylates MUC1 for regulating SRC and beta-catenin signaling. EGFR is known to play critical roles in cellular proliferation, angiogenesis, and cell survival. Several studies have shown that agonist antibodies such as Panitumumab bind EGFR more strongly than EGFR's natural partners. Preclinical studies have shown that panitumumab binds to EGFR and stops ligand-induced receptor autophosphorylation and activation of receptor-associated kinases, thereby causing the inhibition of cell growth, induction of apoptosis, downregulation of the production of pro-inflammatory cytokines and vascular growth factors, and internalization of the EGFR. Studies with in vitro and in vivo experimental models have demonstrated that the neutralization of EGFR with Panitumumab leads to cell cycle arrest and inhibition of tumor growth.